Impact of simulated reduced injected dose on the assessment of amyloid PET scans.

Alzheimer’s disease Amyloid Dose reduction Neuroimaging PET

Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
28 Oct 2023
Historique:
received: 11 07 2023
accepted: 15 10 2023
medline: 29 10 2023
pubmed: 29 10 2023
entrez: 28 10 2023
Statut: aheadofprint

Résumé

To investigate the impact of reduced injected doses on the quantitative and qualitative assessment of the amyloid PET tracers [ Cognitively impaired and unimpaired individuals (N = 250, 36% Aβ-positive) were included and injected with [ At 5% injected dose, change in SUVR was 3.72% and 3.12%, with absolute change in Centiloid 3.35CL and 4.62CL, for [ This proof-of-concept study showed that for both [

Identifiants

DOI: 10.1007/s00259-023-06481-0 PMID: 37897616
pubmed: 37897616
doi: 10.1007/s00259-023-06481-0
pii: 10.1007/s00259-023-06481-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Innovative Medicines Initiative
ID : 115372
Organisme : Innovative Medicines Initiative
ID : 115952

Informations de copyright

© 2023. The Author(s).

Références

Johnson KA, Sperling RA, Gidicsin CM, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9:S72–83.
pubmed: 23375563 pmcid: 3800236 doi: 10.1016/j.jalz.2012.10.007
Lowe SL, Duggan Evans C, Shcherbinin S, et al. Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. J Prev Alzheimers Dis. 2021;8:414–24.
pubmed: 34585215
Chung S, Kim H-J, Jo S, et al. Patterns of Focal Amyloid Deposition Using 18F-Florbetaben PET in Patients with Cognitive Impairment. Diagnostics. 2022;12:1357.
pubmed: 35741166 pmcid: 9221882 doi: 10.3390/diagnostics12061357
Battle MR, Pillay LC, Lowe VJ, et al. Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods. EJNMMI Res. 2018;8:107.
pubmed: 30519791 pmcid: 6281542 doi: 10.1186/s13550-018-0456-7
Bucci M, Savitcheva I, Farrar G, et al. A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. Eur J Nucl Med Mol Imaging. 2021;48:2183–99.
pubmed: 33844055 pmcid: 8175298 doi: 10.1007/s00259-021-05311-5
Heurling K, Leuzy A, Zimmer ER, Lubberink M, Nordberg A. Imaging β-amyloid using [18F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. Eur J Nucl Med Mol Imaging. 2016;43:362–73.
pubmed: 26440450 doi: 10.1007/s00259-015-3208-1
Keppler JS, Conti PS. A Cost Analysis of Positron Emission Tomography. Am J Roentgenol. 2001;177:31–40.
doi: 10.2214/ajr.177.1.1770031
Devine CE, Mawlawi O. Radiation Safety With Positron Emission Tomography and Computed Tomography. Semin Ultrasound CT MRI. 2010;31:39–45.
doi: 10.1053/j.sult.2009.09.005
Muirhead CR, O’Hagan JA, Haylock RGE, et al. Mortality and cancer incidence following occupational radiation exposure: third analysis of the National Registry for Radiation Workers. Br J Cancer. 2009;100:206–12.
pubmed: 19127272 pmcid: 2634664 doi: 10.1038/sj.bjc.6604825
Schonfeld SJ, Lee C, Berrington de González A. Medical Exposure to Radiation and Thyroid Cancer. Clin Oncol. 2011;23:244–50.
doi: 10.1016/j.clon.2011.01.159
Becker GA, Ichise M, Barthel H, et al. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains. J Nucl Med Off Publ Soc Nucl Med. 2013;54:723–31.
Nelissen N, Laere KV, Thurfjell L, et al. Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease. J Nucl Med. 2009;50:1251–9.
pubmed: 19617318 doi: 10.2967/jnumed.109.063305
Carson RE, Naganawa M, Toyonaga T, et al. Imaging of Synaptic Density in Neurodegenerative Disorders. J Nucl Med. 2022;63:60S-67S.
pubmed: 35649655 doi: 10.2967/jnumed.121.263201
Petersen GC, Roytman M, Chiang GC, Li Y, Gordon ML, Franceschi AM. Overview of tau PET molecular imaging. Curr Opin Neurol. 2022;35:230–9.
pmcid: 9011369 doi: 10.1097/WCO.0000000000001035
Aide N, Lasnon C, Kesner A, et al. New PET technologies – embracing progress and pushing the limits. Eur J Nucl Med Mol Imaging. 2021;48:2711–26.
pubmed: 34081153 pmcid: 8263417 doi: 10.1007/s00259-021-05390-4
Slomka PJ, Pan T, Germano G. Recent Advances and Future Progress in PET Instrumentation. Semin Nucl Med. 2016;46:5–19.
pubmed: 26687853 doi: 10.1053/j.semnuclmed.2015.09.006
Badawi RD, Shi H, Hu P, et al. First Human Imaging Studies with the EXPLORER Total-Body PET Scanner*. J Nucl Med. 2019;60:299–303.
pubmed: 30733314 pmcid: 6424228 doi: 10.2967/jnumed.119.226498
Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol. 2010;68:319–29.
pubmed: 20687209 doi: 10.1002/ana.22068
Herholz K, Evans R, Anton-Rodriguez J, Hinz R, Matthews JC. The effect of 18F-florbetapir dose reduction on region-based classification of cortical amyloid deposition. Eur J Nucl Med Mol Imaging. 2014;41:2144–9.
pubmed: 25002030 doi: 10.1007/s00259-014-2842-3
Bohorquez SS, Barret O, Tamagnan G, et al. Assessing optimal injected dose for tau PET imaging using [18F]GTP1 (Genentech Tau Probe 1). J Nucl Med. 2017;58:848–848.
Fällmar D, Lilja J, Kilander L, et al. Validation of true low-dose 18F-FDG PET of the brain. Am J Nucl Med Mol Imaging. 2016;6:269–76.
pubmed: 27766185 pmcid: 5069279
Prieto E, García-Velloso MJ, Rodríguez-Fraile M, et al. Significant dose reduction is feasible in FDG PET/CT protocols without compromising diagnostic quality. Phys Med. 2018;46:134–9.
pubmed: 29519399 doi: 10.1016/j.ejmp.2018.01.021
Soret M, Piekarski E, Yeni N, et al. Dose Reduction in Brain [18F]FDG PET/MRI: Give It Half a Chance. Mol Imaging Biol. 2020;22:695–702.
pubmed: 31286349 doi: 10.1007/s11307-019-01398-3
Gatidis S, Würslin C, Seith F, Schäfer JF. Towards tracer dose reduction in PET studies: Simulation of dose reduction by retrospective randomized undersampling of list-mode data. Hell J Nucl Med. 2016;19:15–8.
pubmed: 26929936
Oehmigen M, Ziegler S, Jakoby BW, Georgi J-C, Paulus DH, Quick HH. Radiotracer Dose Reduction in Integrated PET/MR: Implications from National Electrical Manufacturers Association Phantom Studies. J Nucl Med. 2014;55:1361–7.
pubmed: 25006216 doi: 10.2967/jnumed.114.139147
Mehranian A, Bland J, McGinnity CJ, Hammers A, Reader AJ. Clinical Assessment Of MR-Assisted PET Image Reconstruction Algorithms for Low-Dose Brain PET Imaging. In: 2019 IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC). 2019:1–3.
Lartizien C, Aubin J-B, Buvat I. Comparison of bootstrap resampling methods for 3-D PET imaging. IEEE Trans Med Imaging. 2010;29:1442–54.
pubmed: 20409989 doi: 10.1109/TMI.2010.2048119
Frisoni GB, Barkhof F, Altomare D, et al. AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimers Dement J Alzheimers Assoc. 2019;15:388–99.
doi: 10.1016/j.jalz.2018.09.003
Lopes Alves I, Collij LE, Altomare D, et al. Quantitative amyloid PET in Alzheimer’s disease: the AMYPAD prognostic and natural history study. Alzheimers Dement. 2020;16:750–8.
pubmed: 32281303 pmcid: 7984341 doi: 10.1002/alz.12069
Iaccarino L, La Joie R, Koeppe R, et al. rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data. Neuroimage. 2022;246:118775.
pubmed: 34890793 doi: 10.1016/j.neuroimage.2021.118775
Bourgeat P, Doré V, Burnham SC, et al. β-amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3. Neuroimage. 2022;262:119527.
pubmed: 35917917 doi: 10.1016/j.neuroimage.2022.119527
Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1-15.e4.
pubmed: 25443857 doi: 10.1016/j.jalz.2014.07.003
Luckett ES, Schaeverbeke J, De Meyer S, et al. Longitudinal changes in 18F-flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: methodological considerations. Neuroimage Clin. 2023;37:103321.
pubmed: 36621019 pmcid: 9850036 doi: 10.1016/j.nicl.2023.103321
Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968–80.
pubmed: 16530430 doi: 10.1016/j.neuroimage.2006.01.021
Collij LE, Heeman F, Salvadó G, et al. Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology. 2020;95:e1538–53.
pubmed: 32675080 pmcid: 7713745 doi: 10.1212/WNL.0000000000010256
Palmqvist S, Schöll M, Strandberg O, et al. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017;8:1214.
pubmed: 29089479 pmcid: 5663717 doi: 10.1038/s41467-017-01150-x
Vizamyl. [Internet]. [cited 2023 March 6] ] https://www.gehealthcare.in/-/jssmedia/widen/2018/01/25/0204/gehealthcarecom/migrated/2018/02/19/0834/gatekeeperclinical-product-infovizamylgehealthcarevizamylprescribinginformationpdf.pdf?rev=-1&hash=6389279151DA03442BD67470D93050F3 .
Pemberton HG, Collij LE, Heeman F, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49:3508–28.
pubmed: 35389071 pmcid: 9308604 doi: 10.1007/s00259-022-05784-y
Presotto L, Shekari M, Collij LE, et al. Amyloid PET centiloid: impact of calibration and processing steps. CTAD. 2022; p 83.
Su Y, Flores S, Hornbeck RC, et al. Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. NeuroImage Clin. 2018;19:406–16.
pubmed: 30035025 pmcid: 6051499 doi: 10.1016/j.nicl.2018.04.022
Heeman F, Hendriks J, Lopes Alves I, et al. [11C]PIB amyloid quantification: effect of reference region selection. EJNMMI Res. 2020;10:123.
pubmed: 33074395 pmcid: 7572969 doi: 10.1186/s13550-020-00714-1
Lopes Alves I, Heeman F, Collij LE, et al. Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging. Alzheimers Res Ther. 2021;13:82.
pubmed: 33875021 pmcid: 8056524 doi: 10.1186/s13195-021-00819-2
Timmers T, Ossenkoppele R, Visser D, et al. Test-retest repeatability of [18F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2020;40:2464–74.
doi: 10.1177/0271678X19879226
C. Rowe C, Rowe CC, Pejoska S, et al. Test-retest variability studies in Alzheimer’s disease and normal ageing of the new amyloid imaging agent [18F]BAY 94–9172. Alzheimers Dement 2009;5:P262-P263.
Collij LE, Salvadó G, Shekari M, et al. Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. Eur J Nucl Med Mol Imaging. 2021;48:2169–82.
pubmed: 33615397 pmcid: 8175297 doi: 10.1007/s00259-020-05174-2
Walker Z, Inglis F, Sadowsky C, et al. Reproducibility of [18f]flutemetamol pet amyloid image interpretation. J Neurol Sci. 2013;333:e352.
doi: 10.1016/j.jns.2013.07.1294
Collij LE, Konijnenberg E, Reimand J, et al. Assessing Amyloid Pathology in Cognitively Normal Subjects Using 18F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. J Nucl Med. 2019;60:541–7.
pubmed: 30315145 pmcid: 6448465 doi: 10.2967/jnumed.118.211532
Sabri O, Seibyl J, Rowe C, Barthel H. Beta-amyloid imaging with florbetaben. Clin Transl Imaging. 2015;3:13–26.
pubmed: 25741488 pmcid: 4339690 doi: 10.1007/s40336-015-0102-6
Barthel H, Gertz H-J, Dresel S, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–35.
pubmed: 21481640 doi: 10.1016/S1474-4422(11)70077-1
McHugh ML. Interrater reliability: the kappa statistic. Biochem Medica. 2012;22:276–82.
doi: 10.11613/BM.2012.031

Auteurs

Peter Young (P)

Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
Department of Psychiatry and Neurochemistry, Institute of Physiology and Neuroscience, University of Gothenburg, Gothenburg, Sweden.
ORCID: 0000-0002-4818-4270

Fiona Heeman (F)

Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
Department of Psychiatry and Neurochemistry, Institute of Physiology and Neuroscience, University of Gothenburg, Gothenburg, Sweden.
Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.
ORCID: 0000-0001-7769-8329

Jan Axelsson (J)

Department of Radiation Sciences, Radiation Physics, Umeå University, Umeå, Sweden.
ORCID: 0000-0002-3731-3612

Lyduine E Collij (LE)

Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.
Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
ORCID: 0000-0001-6263-1762

Anne Hitzel (A)

Department of Nuclear Medicine, Toulouse University Hospital, Toulouse, France.

Amirhossein Sanaat (A)

Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland.
ORCID: 0000-0001-8437-2060

Aida Niñerola-Baizan (A)

Nuclear Medicine Department, Hospital Clínic Barcelona, Barcelona, Spain.
Biomedical Research Networking Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), ISCIII, Barcelona, Spain.
ORCID: 0000-0002-7306-5775

Andrés Perissinotti (A)

Nuclear Medicine Department, Hospital Clínic Barcelona, Barcelona, Spain.
Biomedical Research Networking Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), ISCIII, Barcelona, Spain.
ORCID: 0000-0003-4190-2425

Mark Lubberink (M)

Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0001-8324-7399

Giovanni B Frisoni (GB)

Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.
Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland.
ORCID: 0000-0002-6419-1753

Habib Zaidi (H)

Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland.
Geneva University Neurocenter, Geneva University, Geneva, Switzerland.
Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Department of Nuclear Medicine, University of Southern Denmark, Odense, Denmark.
ORCID: 0000-0001-7559-5297

Frederik Barkhof (F)

Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.
UCL Institute of Neurology, London, UK.
ORCID: 0000-0003-3543-3706

Gill Farrar (G)

GE Healthcare, Amersham, UK.
ORCID: 0000-0002-0726-723X

Suzanne Baker (S)

Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, USA.
Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, United States.
ORCID: 0000-0003-0209-3127

Juan Domingo Gispert (JD)

Barcelona βeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, Madrid, Spain.
Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Universitat Pompeu Fabra, Barcelona, Spain.
ORCID: 0000-0002-6155-0642

Valentina Garibotto (V)

Division of Nuclear Medicine and Molecular Imaging, University Hospitals of Geneva; NIMTLab; Center for Biomedical Imaging (CIBM), University of Geneva, Geneva, Switzerland.
ORCID: 0000-0003-2422-698X

Anna Rieckmann (A)

Institute for Psychology, Universität Der Bundeswehr München, Neubiberg, Germany.
ORCID: 0000-0002-5389-1578

Michael Schöll (M)

Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden. michael.scholl@neuro.gu.se.
Department of Psychiatry and Neurochemistry, Institute of Physiology and Neuroscience, University of Gothenburg, Gothenburg, Sweden. michael.scholl@neuro.gu.se.
Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK. michael.scholl@neuro.gu.se.
Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden. michael.scholl@neuro.gu.se.
ORCID: 0000-0001-7800-1781

Classifications MeSH